Your Messages Inbox
Your Article Summary
See Latest ArticlesAllos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Allos Therapeutics, 03/26/09
Allos Therapeutics, Inc. announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the use of pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The Company has requested a priority review of the application, which, if granted, would give the FDA six months from receipt of the submission to take action on the application. PTCL comprises a biologically diverse group of hematologic malignancies that typically has a worse prognosis than other types of lymphoma and is less responsive to traditional chemotherapy regimens.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Bayer's Betaferon approved in China for Treatment of Multiple Sclerosis
BayNews International, 12/02/09
Article Search
Sponsor